The stock of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) is now priced at $0.54 and the shares are -0.02 points down or -4.67% lower compared to its previous closing price of $0.56. The stock had 1.849 million contracts set over the past session. EYPT shares’ daily volume is compared to its average trading volume at 2.45 million shares. However, it has a float of 124 million and although its performance was -12.24% over the week, it’s one to watch. It means the stock’s downside potential is -100% with the EYPT share price recently placing at $0.52 to $0.5559. However, some brokerage firms have priced the stock below the average, including one that has called $0.8.
The shorts are running away from the EyePoint Pharmaceuticals, Inc. stock, with the latest data on short interest released on August 14, 2020, showing that short interest numbers in the EYPT shares have declined. Short interest in the stock represents just 1.56% of its float, but the volume has dropped by -55666. The volume of shorted shares dropped to 1.93 million from 1.986 million shares over the last two weeks. The average intraday trading volume has been 653487 shares, which means that days to cover moved to roughly 2.954063.
In the last trading session, EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) dropped by -$0.0746 over the week and lost -$0.1707 on its 20-day. The stock’s high in the recent session is lower when compared to its 52-week high of $2.69. The stock recorded its established 52-week high on 10/21/19.
Since 08/19/20, the stock has traded to a low of $0.51 at 4.92%, an encouraging piece of data likely to interest most investors out to exploit the stock’s recent surge. The stock has a beta allocation of 1.18. Being above 1 means that the stock’s volatility is higher than the market and traders are keenly watching it.
Looking at current readings, EyePoint Pharmaceuticals, Inc.’s two-week RSI is 38.99. This suggests that the stock is neutral at the moment and that EYPT shares’ price movement remains stable. The stochastic readings are equally revealing at 10.97% meaning the EYPT share price is currently in overbought territory.
The technical chart shows that the EYPT stock will likely settle at between $0.554 and $0.5729 per share. However, if the stock dips below $0.5181, then its market would become much weaker. Any downside could see the stock price sliding to levels as low as $0.5011.
Currently, the stock is trading in the red of MACD, with a reading of -0.0146. Investors always pay attention to any move above or below the zero-line, mainly because the indicator points to the position of the stock’s short-term average relative to its long-term measure. A MACD -a reading above the zero line means that the short-term is above the long-term average. This scenario implies that there is an upward momentum. The opposite is true when the MACD falls below the zero-line.
Analysts at B. Riley FBR cut their recommendation for EYPT from Buy to Neutral in April 06 review while maintai their target price of $4 to $1. Laidlaw analysts see the stock as a Buy with a target price of $5 in a flash note released to investors on November 04 resuming covering the stock. Guggenheim analysts see the stock as Buy when the analysts initiated the share price coverage on September 12.
The average rating for the EYPT equity is 2.25 and is currently gathering a bullish momentum. Of 4 analysts tracking EyePoint Pharmaceuticals, Inc. polled by Reuters, 2 rated EYPT as a hold. The remaining 2 analysts were split evenly. However, the split wasn’t equal as a majority (2) rated it as a buy or strong buy. 0 analyst advised investors against buying the stock or to sell if they own any of the stock.
Zacks Consensus Estimate forecasts that the current-quarter revenues for EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) will decrease by about -99.8%, which will see them reach $8.04 million. The company’s full-year revenues are, however, expected to increase by about 30.01%, up from $20.36 million to $26.47 million. EYPT’s expected adjusted earnings should drop almost -53.33% to end up at -$0.07 per share, while for the fiscal year, analysts project the company’s earnings to drop by about -33.33% to record -$0.36/share.